Related references
Note: Only part of the references are listed.Serum YKL-40 as a marker for cervical adenocarcinoma
A. Mitsuhashi et al.
ANNALS OF ONCOLOGY (2009)
Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population
Julia S. Johansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis
Chun Geun Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
R. Shao et al.
ONCOGENE (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects
Julia S. Johansen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients
Anne K. Mylin et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival
Anne Roslind et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
A chitinase-like protein in the lung and circulation of patients with severe asthma
Geoffrey L. Chupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Evolution of mammalian chitinase (-like) members of family 18 glycosyl hydrolases
Anton P. Bussink et al.
GENETICS (2007)
Is YKL-40 a new therapeutic target in cancer?
Julia S. Johansen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Preoperative serum YK-L-40 is a marker for detection and prognosis of endometrial cancer
Catherine S. M. Diefenbach et al.
GYNECOLOGIC ONCOLOGY (2007)
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
Adilia Hormigo et al.
CLINICAL CANCER RESEARCH (2006)
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma
Christopher E. Pelloski et al.
CLINICAL CANCER RESEARCH (2006)
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma
K Brasso et al.
PROSTATE (2006)
Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma
H Schmidt et al.
CANCER (2006)
Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes
AD Recklies et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia
OJ Bergmann et al.
CLINICAL CANCER RESEARCH (2005)
Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer
N Junker et al.
LUNG CANCER (2005)
Early detection and prognosis of ovarian cancer using serum YKL-40
J Dupont et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
High serum YKL-40 level in patients with small cell lung cancer is related to early death
JS Johansen et al.
LUNG CANCER (2004)
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer:: From the German and Swiss Lung Cancer Study Group
E Laack et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells
KC Nishikawa et al.
EXPERIMENTAL CELL RESEARCH (2003)